SPXU vs XBI
ProShares UltraPro Short S&P500 vs SPDR S&P Biotech ETF
SPXU$34.75
ProShares UltraPro Short S&P500
3x inverse daily performance of the S&P 500.
Expense: 0.90%Yield: 6.05%
XBI$156.41
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.35%
Quick take
- • XBI has the lower expense ratio at 0.35% vs 0.90% for SPXU.
- • SPXU pays a higher dividend yield (6.05%).
Side-by-side metrics
| Metric | SPXU | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.90% | 0.35% |
Dividend yield Trailing 12-month yield. | 6.05% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $428M | $10.92B |
YTD return | -25.45% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | -2.62 | 1.01 |
P/E ratio | — | — |
Last price | $34.75 | $156.41 |
Inception | — | — |
Issuer | ProShares | State Street |
SPXU top holdings
Top holdings · SPXU
| IQMM | ProShares GENIUS Money Market ETF | 89.37% |
XBI top holdings
Top holdings · XBI
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%
About SPXU
SPXU (ProShares UltraPro Short S&P500) is 3x inverse daily performance of the S&P 500. Managed by ProShares, the fund carries $428M in assets under management, an expense ratio of 0.90%, a dividend yield of 6.05%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 89.4% of the portfolio.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.